Results
Aarti Drugs Q4 Revenue Up 6% YoY, PAT Down 12%
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore, a 6% YoY growth, while PAT declined 12% to ₹55.3 crore.
EBITDA was flat YoY at ₹96.6 crore, with margins contracting 60 bps to 13.4%,
